当前位置: 首页 > 期刊 > 《中国现代医生》 > 201816
编号:13580888
尿液核基质蛋白22检测在膀胱癌诊断中的临床应用(3)
http://www.100md.com 2018年6月5日 《中国现代医生》 201816
     [8]何安仁,宋洪飛,史涛坪.腹腔镜与开放性根治术治疗膀胱癌的疗效比较[J].山西医药杂志,2018,47(2):174-176.

    [9]吴静,方克伟.尿液中核基质蛋白22联合端粒酶活性检测诊断膀胱癌的实验研究[J].现代肿瘤医学,2013, 21(3):595-598.

    [10]徐子程,蔡宏宙,喻彬,等.膀胱肿瘤相关抗原在中国人群膀胱尿路上皮癌诊断中的应用[J].临床泌尿外科杂志,2016,31(10):900-902.

    [11]Keesee SK,Briggman JV,Thill G,et a1.Utilization of nuclear matrix proteins for cancer diagnosis[J].Crit Rev Eukaryot GencExpr,1996,6(2-3):189-214.

    [12]He H,Han C,Hao L,et al.Immuno Cyt test compared to cytology in the diagnosis of bladder cancer:A meta-analysis[J].Oncol Lett,2016,12(1):83-88.

    [13]Yafi FA,Brimo F,Steinberg J,et a1.Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer[J].Urol Oncol,2015, 33(2):25-31.

    [14]Todenhofer T,Hennenlotter J,Guttenberg P,et a1.Prognostic relevance of positive urine markep3 in pafients with negative cystoscoPY during surveillance of bladder cancer[J].BMC Cancer,2015,(2015):155.

    [15]杨青,李俊.膀胱癌尿脱落细胞学检查与尿液肿瘤标志物研究进展[J].安徽医药,2012,16(4):528-529.

    (收稿日期:2018-02-05), http://www.100md.com(周巍)
上一页1 2 3